WO2025006573A2 - Séquences pmcv à codons optimisés - Google Patents

Séquences pmcv à codons optimisés Download PDF

Info

Publication number
WO2025006573A2
WO2025006573A2 PCT/US2024/035572 US2024035572W WO2025006573A2 WO 2025006573 A2 WO2025006573 A2 WO 2025006573A2 US 2024035572 W US2024035572 W US 2024035572W WO 2025006573 A2 WO2025006573 A2 WO 2025006573A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
nucleic acid
codon optimized
sequence
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/035572
Other languages
English (en)
Other versions
WO2025006573A3 (fr
Inventor
Jared PATCH
Shrinivasrao P. MANE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Elanco US Inc
Original Assignee
Intervet International BV
Elanco US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV, Elanco US Inc filed Critical Intervet International BV
Priority to EP24832850.2A priority Critical patent/EP4735031A2/fr
Publication of WO2025006573A2 publication Critical patent/WO2025006573A2/fr
Publication of WO2025006573A3 publication Critical patent/WO2025006573A3/fr
Priority to DKPA202570141A priority patent/DK202570141A1/en
Priority to NO20251666A priority patent/NO20251666A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Definitions

  • the disclosure relates to sequences of Piscine Myocarditis Virus (PMCV) sequences that have been modified to comprise codons optimized for expression in cells.
  • PMCV Piscine Myocarditis Virus
  • CMS Cardiomyopathy syndrome
  • PMCV Piscine Myocarditis Virus
  • PMCV encodes at least three major proteins: a capsid (ORF1), an RNA-dependent RNA polymerase (ORF2), and a structural protein of unknown function (ORF3) that may be involved in virus assembly or egress.
  • ORF1 capsid
  • ORF2 RNA- dependent RNA polymerase
  • ORF3 structural protein of unknown function
  • the present disclosure in one aspect, provides nucleic acid molecules (e.g., described in one aspect as sequences) encoding Piscine Myocarditis Virus (PMCV) protein(s).
  • the nucleic acid sequences of the present disclosure have been modified to comprise codons optimized for improved expression in cells.
  • SEQ ID NO: 1 corresponds to a codon optimized sequence for ORF_1 of PMCV.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO: 1 is provided.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 1 is provided.
  • a codon optimized nucleic acid sequence consisting of SEQ ID NO: 1 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 1 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 1 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 1 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 1 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO: 1 is provided.
  • SEQ ID NO: 2 corresponds to a codon optimized sequence for ORF_3 of PMCV.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO:
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence consisting of SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 2 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 2 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 2 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO: 2 is provided.
  • SEQ ID NO: 3 corresponds to a codon optimized sequence for ORF_3 FR13 of PMCV.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO: 3 is provided.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 3 is provided.
  • a codon optimized nucleic acid sequence consisting of SEQ ID NO: 3 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 3 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO: 3 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 3 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO: 3 is provided.
  • SEQ ID NO: 4 corresponds to a second codon optimized sequence for ORF_1 of PMCV.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO: 4 is provided.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 4 is provided.
  • a codon optimized nucleic acid sequence consisting of SEQ ID NO: 4 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 4 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO: 4 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 4 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO: 4 is provided.
  • SEQ ID NO: 5 corresponds to a second codon optimized sequence for ORF_3 of PMCV.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO: 5 is provided.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 5 is provided.
  • a codon optimized nucleic acid sequence consisting of SEQ ID NO: 5 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 5 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO: 5 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 5 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO: 5 is provided.
  • SEQ ID NO: 6 corresponds to second codon optimized sequence for ORF_3 FR13 of PMCV.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO: 6 is provided.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO: 6 is provided.
  • a codon optimized nucleic acid sequence consisting of SEQ ID NO: 6 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 6 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO: 6 is provided.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 6 is provided. In an embodiment, a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO: 6 is provided.
  • an expression vector comprises one or more codon optimized nucleic acids sequences, wherein the one or more codon optimized nucleic acids sequences can comprise any of the codon optimized nucleic acid sequences described herein.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO:1.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO:1.
  • a codon optimized nucleic acid sequence consisting of SEQ ID NO:1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO: 1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO: 1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO:1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO: 1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ 1D NO:1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO: 1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO: 1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO:1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO: 1. 14. A codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO: 1.
  • a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO:1.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO:2.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO:2.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO:3.
  • a codon optimized nucleic acid sequence consisting of SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO:3.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO:4.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO:4.
  • 52. A codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO:4.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO:5.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 97% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO:5.
  • a codon optimized nucleic acid sequence comprising SEQ ID NO:6.
  • a codon optimized nucleic acid sequence consisting essentially of SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 80% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 85% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 90% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 91% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 92% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 93% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 94% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 95% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 96% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 98% identical with SEQ ID NO:6.
  • a codon optimized nucleic acid sequence comprising a sequence at least 99% identical with SEQ ID NO:6.
  • An expression vector comprising one or more codon optimized nucleic acids sequences, wherein the one or more codon optimized nucleic acids sequences are selected from any one of clauses 1 to 90 and any combination thereof.
  • Exemplary codon optimized nucleic acid sequence were constructed.
  • the nucleic acid sequences as shown in Table 1 can be utilized according to the present disclosure.
  • sequences include the following:
  • AAGGCTTTAGGGTGGGAGTGTGA (SEQ ID NO: 3)
  • GACTTCCTCGACATTTAA SEQ ID NO: 4
  • Exemplary vectors can be constructed using fusion technology to create various plasmids. For instance, starting with an existing plasmid, a variant plasmid can be designed to include one or more codon optimized nucleic acid sequences of the present disclosure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente divulgation concerne des séquences d'acides nucléiques à codons optimisés codant pour le virus de la myocardite pisciaire (PMCV). L'invention concerne également des vecteurs d'expression comprenant une ou plusieurs des séquences d'acides nucléiques à codons optimisés décrites.
PCT/US2024/035572 2023-06-27 2024-06-26 Séquences pmcv à codons optimisés Ceased WO2025006573A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP24832850.2A EP4735031A2 (fr) 2023-06-27 2024-06-26 Séquences pmcv à codons optimisés
DKPA202570141A DK202570141A1 (en) 2023-06-27 2025-12-12 Codon optimized pmcv sequences
NO20251666A NO20251666A1 (en) 2023-06-27 2025-12-22 Codon optimized pmcv sequences

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363523476P 2023-06-27 2023-06-27
US63/523,476 2023-06-27

Publications (2)

Publication Number Publication Date
WO2025006573A2 true WO2025006573A2 (fr) 2025-01-02
WO2025006573A3 WO2025006573A3 (fr) 2025-03-06

Family

ID=93940162

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/035572 Ceased WO2025006573A2 (fr) 2023-06-27 2024-06-26 Séquences pmcv à codons optimisés

Country Status (4)

Country Link
EP (1) EP4735031A2 (fr)
DK (1) DK202570141A1 (fr)
NO (1) NO20251666A1 (fr)
WO (1) WO2025006573A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615663B1 (fr) * 2003-10-24 2007-12-26 Mologen AG Produit de traitement des infections par leishmania
CA2796178C (fr) * 2010-04-21 2021-02-16 Pharmaq As Sequences d'acide nucleique du virus du syndrome de cardiomyopathie chez les poissons et son utilisation

Also Published As

Publication number Publication date
WO2025006573A3 (fr) 2025-03-06
NO20251666A1 (en) 2025-12-22
DK202570141A1 (en) 2026-01-07
EP4735031A2 (fr) 2026-05-06

Similar Documents

Publication Publication Date Title
US11008564B2 (en) Processing engineered FMDV P1 polypeptide using an alternative TEV protease
Fodor et al. Induction of protective immunity in chickens immunised with plasmid DNA encoding infectious bursal disease virus antigens
Li et al. Enhancement of the immunogenicity of DNA vaccine against infectious bursal disease virus by co-delivery with plasmid encoding chicken interleukin 2
Zhu et al. Preliminary screening and immunogenicity analysis of antigenic epitopes of spring viremia of carp virus
US20250127873A1 (en) Compositions and methods for prevention of piscine myocarditis
EP2989205A1 (fr) Chromosomes artificiels bactériens
US20250057946A1 (en) Use of interferon as an adjuvant in vaccines
RU2018130683A (ru) Аттенуированный вирус инфекционного бронхита
EP2992005B1 (fr) Protéine de spicule mutante étendant le tropisme tissulaire du virus de la bronchite infectieuse (ibv)
CN111040024A (zh) 4型禽腺病毒基因工程疫苗及其制备方法与应用
CN111548394A (zh) 禽法氏囊病毒基因工程疫苗及其制备方法与应用
CN120202019A (zh) 重组lsdv载体口蹄疫抗原构建体
WO2025006573A2 (fr) Séquences pmcv à codons optimisés
US20250057937A1 (en) Compositions and methods for expressing antigens on cell membrane
US20070207167A1 (en) Immunologically enhanced recombinant vaccines
CN110257428B (zh) 一种表达猪圆环病毒3型orf2基因的重组腺病毒及制备方法与应用
Kwon et al. Sequence analysis of the variable VP2 gene of infectious bursal disease viruses passaged in Vero cells
CN1630662A (zh) 兔出血性疾病疫苗及抗原
RU2854997C2 (ru) Использование интерферона в качестве адьюванта в вакцинах
CN120775802B (zh) 一种鲤疱疹病毒3型orf136基因失活株及其制备方法和应用
JP2025091235A (ja) バキュロウイルス発現系を用いて豚熱ウイルスのｅ２サブユニットを発現するためのコンストラクト、およびその利用
Duong et al. Expression and purification capsid proteins Vp0, Vp1 and Vp3 of foot and mouth disease virus type O in Escherichia coli
Negrete-Méndez et al. A Lambda-evo (λevo) phage platform for Zika virus EDIII protein display
CN107245105A (zh) HN‑VP233‑221aa融合蛋白及其制备方法和应用
CN120775801A (zh) 一种鲤疱疹病毒3型orf138基因失活株及其制备方法和应用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: PA202570141

Country of ref document: DK

WWP Wipo information: published in national office

Ref document number: PA202570141

Country of ref document: DK

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24832850

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024832850

Country of ref document: EP

Ref document number: 2026101561

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024832850

Country of ref document: EP

Effective date: 20260127

ENP Entry into the national phase

Ref document number: 2024832850

Country of ref document: EP

Effective date: 20260127

WWP Wipo information: published in national office

Ref document number: 2026101561

Country of ref document: RU